Published in J Virol on December 10, 2014
Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer (2016) 0.88
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. Curr Hematol Malig Rep (2015) 0.82
Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers. Clin Infect Dis (2016) 0.78
High prevalence of infectious adeno-associated virus (AAV) in human peripheral blood mononuclear cells indicative of T lymphocytes as sites of AAV persistence. J Virol (2016) 0.76
Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas (PTCL). Int J Cancer (2016) 0.75
Epigenetic Impact on EBV Associated B-Cell Lymphomagenesis. Biomolecules (2016) 0.75
Recent advances in understanding Epstein-Barr virus. F1000Res (2017) 0.75
Natural variation of Epstein-Barr virus genes, proteins and pri-miRNA (revised). J Virol (2017) 0.75
Heterogeneity of the Epstein-Barr virus major internal repeat reveals evolutionary mechanisms of EBV and a functional defect in the prototype EBV strain B95-8. J Virol (2017) 0.75
Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). Discov Med (2017) 0.75
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med (2004) 5.61
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med (2002) 4.33
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med (1993) 3.64
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol (1990) 3.54
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J Virol (1976) 3.33
The genome of Epstein-Barr virus type 2 strain AG876. Virology (2006) 2.67
Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol (1998) 2.61
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol (2000) 2.04
Detection of a second widespread strain of Epstein-Barr virus. Lancet (1989) 1.93
Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis (2005) 1.81
MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci U S A (2002) 1.79
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood (2011) 1.72
New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol (1987) 1.58
Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis (2007) 1.39
EBV the prototypical human tumor virus--just how bad is it? J Allergy Clin Immunol (2005) 1.38
Epstein-Barr virus immortalizing genes. Trends Microbiol (1995) 1.35
Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus. Virology (1989) 1.35
Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol (1993) 1.31
Human RANTES induces the migration of human T lymphocytes into the peripheral tissues of mice with severe combined immune deficiency. Eur J Immunol (1994) 1.29
Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol (2006) 1.22
Genomic sequencing and comparative analysis of Epstein-Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy. PLoS One (2012) 1.20
Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol (2002) 1.15
Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res (2001) 1.09
Epstein-Barr virus: a paradigm for persistent infection - for real and in virtual reality. Trends Immunol (2008) 1.03
Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J Virol (2008) 1.03
Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood (2010) 1.03
Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders. J Dermatol (2014) 1.01
Current research on chronic active Epstein-Barr virus infection in Japan. Pediatr Int (2014) 0.94
Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases. Cancer Sci (2012) 0.94
Epstein-Barr virus genotypes in AIDS-associated lymphomas are similar to those in endemic Burkitt's lymphomas. Leukemia (1992) 0.92
Isolation and characterization of transformed human T-cell lines infected by Epstein-Barr virus. Blood (1997) 0.92
EBV induces the production and release of IL-8 and macrophage inflammatory protein-1 alpha in human neutrophils. J Immunol (1997) 0.91
Expression of RANTES and MCP-1 in epithelial cells is regulated via LMP1 and CD40. Int J Cancer (2007) 0.87
Activation of human thymocytes after infection by EBV. J Immunol (1995) 0.86
Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. Adv Virus Res (2014) 0.86
Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation. J Virol (2013) 0.85
Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein. Int Immunol (1998) 0.84
IL-8-Induced T-Lymphocyte Migration: Direct as Well as Indirect Mechanisms Methods (1996) 0.82
Demonstration of type II latency in T lymphocytes of Epstein-Barr Virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2012) 0.82
Virus isolation. Methods Mol Biol (2001) 0.82
C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7. PLoS Pathog (2011) 0.81
Cutaneous EBV-positive γδ T-cell lymphoma vs. extranodal NK/T-cell lymphoma: a case report and literature review. J Cutan Pathol (2012) 0.80
Endogenous latent membrane protein 1 in Epstein-Barr virus-infected nasopharyngeal carcinoma cells attracts T lymphocytes through upregulation of multiple chemokines. Virology (2010) 0.79
EBV induces proliferation of immature human thymocytes in an IL-2-mediated response. J Immunol (1996) 0.77
Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses. Antimicrob Agents Chemother (2014) 0.77
The Epstein-Barr Virus BDLF4 Gene Is Required for Efficient Expression of Viral Late Lytic Genes. J Virol (2015) 0.80
Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening. J Clin Virol (2015) 0.80
Epstein-Barr virus infection-induced inflammasome activation in human monocytes. PLoS One (2017) 0.75
Chronic active EBV infection with features of granulomatosis with polyangiitis. Pediatr Int (2016) 0.75
Characterization of a Suppressive Cis-acting Element in the Epstein-Barr Virus LMP1 Promoter. Front Microbiol (2017) 0.75
Epstein-Barr Virus BKRF4 Gene Product Is Required for Efficient Progeny Production. J Virol (2017) 0.75